Cancer physicians' attitudes toward colorectal cancer follow-up

Ann Oncol. 2003 Mar;14(3):400-5. doi: 10.1093/annonc/mdg101.

Abstract

Background: The optimal follow-up strategy for colorectal cancer is unknown.

Materials and methods: We surveyed all Canadian radiation oncologists, medical oncologists and surgeons specializing in colorectal cancer to assess their recommendations for follow-up after potentially curative treatment, the beliefs and attitudes underlying these practices, and the cost implications of different follow-up strategies.

Results: One hundred and sixty practitioners (58%) returned completed surveys. Most recommended clinical assessments every 3-4 months in the first 2 years including carcino-embryonic antigen testing, gradually decreasing in frequency over 5 years. Ninety per cent recommend a surveillance colonoscopy in the first year. The majority felt that specialist involvement in follow-up was important because of the increased opportunities for patients to contribute to research (76%) and teaching (73%). About half felt that specialists were more efficient at providing follow-up than primary care physicians, but these same physicians recommended significantly longer and more expensive follow-up routines on average than others. Primary care physicians were felt to be important allies, especially in managing the psychosocial concerns of patients.

Conclusions: Surveillance practices are generally in keeping with published recommendations. Most specialists feel that they should remain involved in follow-up, but this may result in increased resource utilization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Attitude of Health Personnel*
  • Canada
  • Carcinoembryonic Antigen / analysis
  • Colorectal Neoplasms / pathology*
  • Female
  • Health Care Surveys
  • Humans
  • Male
  • Medical Oncology*
  • Middle Aged
  • Monitoring, Physiologic
  • Neoplasm Recurrence, Local / diagnosis
  • Physician's Role*
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Primary Health Care
  • Radiation Oncology*
  • Treatment Outcome

Substances

  • Carcinoembryonic Antigen